MACH7 TECHNOLOGIES LIMITED — AGM Information 2007

Nov 22, 2007

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

2007 AGM
----- End of picture text -----

Mr John Riemelmoser

A company focused on developing and marketing a unique range of Safety Products led by its flagship – SecureTouch™retractable safety syringe

Founded in 2001 by CEO, John Riemelmoser and listed on ASX in November 2005

Two acquisitions completed in early 2007:

• ProControl Systems in February 2007

• Bagot Press in May 2007

Mission

SafetyMed aims to be a global medical and health products developer, manufacturer and distributor, initially through commercialisation of its retractable syringe technologies and temperature sensitive quality control products.

Safety Medical Products Group

ProControl

SafetyMed

• SafetyMed Bagot Press ProControl • Development and • Leading provider • Control systems commercialisation of printing and and automation of innovative consumables to engineering medical products pharmacies company

• • Production & sales • Customer base of • Customer base of SecureTouch™ >2,000 includes large & retractable safety pharmacies small industrial syringe commenced • FY08 revenue companies

• • Direct sales for AU projected to be • Designed & built & NZ $3.0–3.5m SecureTouch™

• • assembly Agreement with • Selling machine

• Exelint of USA for SecureTouch™& •

• international sales other SafetyMed FY08 revenue products projected to be $1.5–2.0m

Highlights

• Development complete of the Company’s first full Retractable Safety Syringe, SecureTouch™.

• Equipment capable of assembling 5,000 syringes per hour successfully commissioned.

• Awarded AusIndustry Commercial Ready grant of $256k to assist with development of assembly machine.

• Australian and European Manufacturing and Sales Certifications granted.

• Production, Sales and distribution agreement in place with Exelint of USA.

Highlights

• Production and sales commenced in October 2007 – initially to pharmacies via Bagot Press.

• Presentation of SecureTouch™to other private and public sector markets currently underway.

• Production to be scaled up over coming months as demand increases – existing equipment capable of assembling approximately 3 million units per month.

• Recent capital raising to provided funds required to commercialise SecureTouch™.

• Company’s primary objective.

• Development completed with initial production and sales commencing in Oct 2007.

• Only technology to utilise retrofitting process on current standard syringes.

• Advantages:

• Low cost, marginally higher than standard syringe;

• Expandable to full range of sizes;

• Easily adaptable and transportable manufacturing system.

==> picture [403 x 181] intentionally omitted <==

• Exel International strategic alliance to provide access to manufacturing facilities and distribution to overseas markets.

• Sleeve and Locking Mechanism is owned with patent pending by SafetyMed.

• TGA and CE Certifications.

• US based medical products Company.

• Distribution network across US, Japan, Germany and UK.

• Strategic alliance to manufacture and distribute SafetyMed’s SecureTouch™ Retractable syringes.

• Committed to sales of 75 million units over initial two years;

• Sales commitment increasing by 10% per year for five years.

• Initial agreement for a period of five years, with an option of two further five year periods, each exercisable at SafetyMed’s discretion.

• International Production to be based in Seoul, South Korea.

SafetyMed will receive a royalty of USD$0.0135 per unit from the Exel JV.

==> picture [350 x 187] intentionally omitted <==

----- Start of picture text -----

Indicative JV Forecasts
Gross Royalty Gross Royalty
Year Units Sold
Revenue USD Revenue AUD
2008 25,000,000 $343,750 $381,944
2009 50,000,000 $687,500 $763,889
2010 55,000,000 $756,250 $840,278
2011 60,500,000 $831,875 $924,306
2012 66,550,000 $915,063 $1,016,736
Exchange Rate = AUD$0.90
----- End of picture text -----

• Sales in Australia are forecasted to reach 15 million units in 2008, generating revenue in the order of $2.5m at gross margin of approximately 30%.

• Federal Government funded clean needle program first key Australian market –

• opportunity 50m units per annum.

• Capacity of existing assembly equipment is approximately 3 million units per month.

• TGA Certification for the supply and sale of the SecureTouch™Retractable Safety Syringe in Australia.

• The Company received its Australian Conformity Assessment Certification for the manufacture of Retractable Syringes in Australia.

• Only certified Company to manufacture Retractable Syringes in Australia.

• CE Marking Certification for sales into 27 countries of the European Union granted.

• Successfully demonstrated compliance to ISO 13485:2003, the International Harmonised Quality System Standard for Medical Device Manufacturers

• Recognises highest quality standards for production, warehousing, traceability and documentation procedures.

• Development stage.

• Monitors storage and handling of temperature sensitive products.

• Large range of applicable sectors.

• Advantages:

• Simple proven technology;

• Low cost;

• Reliable indication;

• Broad range of temperatures;

• Impervious to external environment.

==> picture [205 x 160] intentionally omitted <==

• Recent acquisition of Bagot Press and ProControl Systems will assist development and commercialisation.

• Development to proceed after commercialisation ™

• of SecureTouch .

Product Development Timeline

May 2007 June 2007 Oct 2007

Nov/Dec 2007 Presentation of SecureTouch™ to private and public sector markets, including Government agencies and medical product distributors Jan 2008 Ramp up to full production upon commissioning of packing equipment & as demand requires TBC

• Two recent appointments have enhanced the management team:

• –

• Chief Financial Officer Tony Mitchell

CFO of GroPep prior to takeover by global biotech company Novozymes A/S Previously held senior financial management positions with Mayne Group, FH Faulding & Coca-Cola Amatil • – Sales & Marketing Manager Chris Harnett Sales & Marketing Manager of BresaGen prior to takeover by global pharmaceutical company Hospira Previously held senior sales & marketing management positions with Novo Nordisk, Australian Medical & Scientific and Jackson Care Technology

• Aims to be a world leader in rapidly growing industry.

• Government regulations changed to promote and enforce the use of safety syringes.

• Expected cheapest products on the market.

• Australian Conformity Assessment Certification: Only company certified to manufacture Retractable Syringes in Australia

• ™

• SecureTouch automated assembly plant completed with initial production commenced in Oct 2007 and full production in early 2008.

• Development of other products and assembly systems accelerated due to recent acquisitions.

• Good position to capitalise on growth opportunities.

• Knowledgeable and experienced Board.